EUCTR2017‐000990‐35‐IT.

Study name	Effects of the antidepressive therapy with agomelatin and escitalopram in people with depression and epilepsy
Methods	A double‐blind randomised study with active control (escitalopram) with parallel groups
Participants	222
Interventions	escitalopram 10 mg daily vs agomelatine 25 mg daily for 6 months
Outcomes	Primary outcome: efficacy (depression BDI‐II) Secondary outcomes: depression (HDRS), quality of life (QOLIE‐31P, quality of life in epilepsy II version), sleep quality (PSQI), daytime sleepiness (ESS), and cognition (MDB)
Starting date	2019
Contact information	Prof. Fabio Placidi
Notes